To include your compound in the COVID-19 Resource Center, submit it here.

Tecentriq could be first front-line SCLC therapy approved in two decades

FDA accepted and granted Priority Review to an sBLA from Genentech Inc. for anti-PD-L1 mAb Tecentriq atezolizumab as first-line treatment of extensive-stage

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE